Andrew Gordon excelled as an Equity Analyst, specializing in biotech and pharmaceutical stocks and options. His research-driven approach involved analyzing Phase I-III studies, company 10-Ks, and independent publications to assess drug efficacy, FDA approval probabilities, and competitive landscapes. Andrew's in-depth evaluations of peak annual sales versus market capitalization enabled successful stock selections, including Madrigal Pharmaceuticals and Hutchmed. His expertise in ADC science and gene therapy wet AMD companies further solidified his analytical prowess. By meticulously reviewing cash flow and financial positions, Andrew ensured precise, profitable trading decisions.